XSHE
300146
Market cap2.38bUSD
Sep 30, Last price
9.43CNY
Name
Byhealth Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
By-health Co., Ltd. operates internationally as a producer and vendor of a diverse range of dietary supplements. Its comprehensive portfolio encompasses essential nutrients like proteins, vitamins, and minerals, in addition to specialized solutions addressing numerous health needs. These include offerings for supporting bone and joint integrity, promoting cardiovascular and brain health, enhancing beauty, boosting immunity, assisting with weight control, improving vigor, nourishing eyes, aiding sleep, managing blood sugar, optimizing memory, and supporting reproductive wellness. The company also provides tailored nutrition for children, expectant mothers, and the well-being of the liver, digestive tract, and stomach. Sold under the "By-health" and "GymMax" labels, these products are designed for all age groups—children, adult men and women, and seniors—and are distributed globally through a multi-channel approach involving wholesale partners, retail stores, and online platforms. Established in 1995, By-health Co., Ltd. is based in Guangzhou, China. The firm was previously known as Guangdong By-Health Biotechnology Co., Ltd. until its rebranding in April 2012.
Key people
Yunchao Liang
Chairman of the Board · since 2008
Bailin He
Chief Financial Officer · since 2023
Liangping Cai
Chief Operating Officer, Deputy General Manager · since 2017
Hong Chen
Deputy General Manager · since 2014
Jinyin Tang
Secretary of the Board · since 2018
Shuisheng Liang
Vice Chairman of the Board · since 2012
Zhicheng Lin
General Manager, Director · since 2015
Hui Tang
Director · since 2015
Chuanyuan Deng
Independent Director · since 2020
Independent Director · since 2023
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||